GlassScriptPhysician profile
Joshua Jackson
NPI 1376902221
$3,396.97
in general payments reported to CMS, 2019-2025
27 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what 88% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $567 · 2022: $635 · 2023: $294 · 2024: $814 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,194.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $657.25 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $549.16 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Actelion Pharmaceuticals US, INC. | $300.35 | 2021-2025 | Opsumit, Uptravi, Opsynvi |
| Ani Pharmaceuticals, INC. | $196.42 | 2024-2025 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $173.72 | 2022-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.41 | 2021-2024 | Ofev |
| Shionogi INC | $135.92 | 2021-2025 | Fetroja |
| Abiomed | $130.30 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.94 | 2022-2025 | Glassia, Cuvitru |
| Grifols USA, LLC | $125.15 | 2022-2025 | Prolastin-C Liquid |
| Edwards Lifesciences Corporation | $123.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $114.12 | 2021-2024 | |
| Lilly USA, LLC | $91.80 | 2025 | Zepbound |
| Abbvie INC. | $73.40 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $58.82 | 2021-2024 | Keytruda |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $55.38 | 2023-2025 | Tyvaso, Tyvaso |
| Viatris Specialty LLC | $50.04 | 2025 | Yupelri |
| Inogen, INC. | $39.00 | 2023-2024 | Inogen |
| Jazz Pharmaceuticals INC. | $38.79 | 2021-2024 | |
| Mallinckrodt Hospital Products INC. | $35.63 | 2022-2024 | Terlivaz |
| Vapotherm INC | $34.49 | 2021 | |
| Insmed, INC. | $30.25 | 2023 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $22.63 | 2022 | |
| Avadel Cns Pharmaceuticals, LLC | $22.35 | 2024 | Lumryz |
| Electromed, INC. | $22.02 | 2025 | Smartvest |
| Amgen INC. | $19.54 | 2025 | Tezspire |
| Baxter Healthcare | $15.77 | 2024 | Hillrom - Vest System Model 105 Home Care |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.